Cobus Loots, CEO of Pan African Resources, on delivering sector-leading returns for shareholders. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGlaxosmithkline Share News (GSK)

Share Price Information for Glaxosmithkline (GSK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,745.00
Bid: 1,745.00
Ask: 1,745.50
Change: -30.00 (-1.69%)
Spread: 0.50 (0.029%)
Open: 1,770.00
High: 1,770.00
Low: 1,744.50
Prev. Close: 1,775.00
GSK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

LONDON MARKET CLOSE: Cooling US inflation triggers risk-on rally

Thu, 10th Nov 2022 17:01

(Alliance News) - Equities in Europe were celebrating a cooler-than-expected US CPI print on Thursday, which gave rise to hopes that peak inflation in the US has passed.

The FTSE 100 index closed up 79.09 points, 1.1%, at 7,375.34. The FTSE 250 ended up 728.24 points, 3.9%, at 19,377.24, and the AIM All-Share closed up 1.8%, or 15.22 points, at 841.57

The indices had a mostly cautious day, trading down 0.1%, up 0.1% and down 0.4% respectively at midday in London, before shooting up on the relase of the US data.

The Cboe UK 100 ended up 1.3% at 739.22, the Cboe UK 250 closed up 3.9% at 16,715.65, and the Cboe Small Companies ended up 1.3% at 12,683.16.

Equities in Europe were similarly upbeat, as the CAC 40 in Paris ended up 1.9%, while the DAX 40 in Frankfurt outperformed, jumping 3.6%.

US inflation slowed in October, the latest data from the US Bureau of Labor Statistics showed, undershooting market expectations.

The consumer price index rose 7.7% in October against the prior year, slowing from the 8.2% rise recorded in September. Market consensus, as cited by FXStreet, had expected for inflation to cool to 8.0% in October.

Against the previous month, consumer prices rose by 0.4% in October, unchanged from September and in-line with market consensus.

With the figure coming in below expectations, many will view the reading as a case for the US Federal Reserve to be less assertive and hike rates by 50 basis point or less in December. In each of the last four meetings it has raised rates by 75 basis points.

"The cool inflation print should mean the beginning of the end for inflation fears, and the Fed will feel much more comfortable ramping down," said SPI Asset Management's Stephen Innes.

Strengthening the case for a more dovish stance in the months to come was data showing a rise in jobless claims in the US.

According to CME's FedWatch tool, the probability of a 50 basis point hike in the Fed's December meeting now stands at 81%, compared to 57% on Wednesday.

Data from the Department of Labor showed jobless claims were up in the week ending November 5.

It said 225,000 new claims were made, a rise of 7,000 from the previous week's revised level which was increased to 218,000 from 217,000.

In the September minutes from the Federal Open Market Committee, policymakers had highlighted that a softening in the labour market would likely be necessary to reign in inflation.

However, AJ Bell's Danni Hewson cautioned: "Whilst today's bad jobs news will be viewed by markets as good news, employment is still startlingly high for a country expecting a serious growth slowdown and that means competition for workers will keep wages elevated for at least the short term."

Stocks in New York were surging at the London equities close, with the DJIA up 2.8%, the S&P 500 index up 4.3%, and the Nasdaq Composite up 5.8%.

The dollar, meanwhile, slumped against major currencies.

The pound was quoted at USD1.1661 late Thursday, up sharply from USD1.1416 at the London equities close on Wednesday. The euro traded at USD1.0162, up from USD1.0049. Against the yen, the dollar was trading at JPY141.78, a steep fall from JPY146.00 on Wednesday.

The lower dollar drove the price of gold higher. Gold was quoted at USD1,745.45 an ounce, sharply higher against USD1,713.97 at the London equities close on Wednesday.

In London, oil stocks BP, Shell and Harbour Energy shed 2.4%, 2.9% and 2.1% as the dollar-earners felt the hit from a weaker greenback, and a weak demand outlook after China recommitted to its "unswerving" zero-Covid policy.

The price of a barrel of Brent remained fairly steady, however, quoted at USD93.90 late Thursday in London, up slightly from USD93.74 late Wednesday.

GSK consumer healthcare spin-off Haelon fell 2.8%.

For the third quarter of 2022, the Sensodyne and Panadol-owner reported revenue growth of 16% year-on-year to GPB2.89 billion from GBP2.49 billion.

Pretax profit, however, slipped to GBP495 million from GBP507 million. It blamed the dip on standalone costs and adverse foreign exchange rates, specifically related to the Swiss franc and US dollar strength.

GSK ended the day mostly unscathed, up 0.1%.

B&M European Value lost 4.5%, as it reported shrinking interim profit and a dip in UK revenue.

The retailer reported pretax profit in the six months to September 24 fell 17% to GBP201 million from GBP241 million a year ago. Revenue grew 1.8% to GBP2.31 billion from GBP2.27 billion.

Revenue from UK B&M fell by 0.9% to GBP1.89 billion from GBP1.91 billion, while revenue in France rose 18% to GBP184 million from GBP155 million. Heron Foods revenue increased 15% to GBP233 million from GBP203 million.

However, the budget retailer said trading has been good in the early stage of the "golden quarter", which contains the key Christmas trading period.

Elsewhere in the FTSE 100, the mood was jubilant.

Property stocks were among the highest gainers, with Unite Group up 6.2%, British Land rising 6.4%, Land Securities rising 5.9%, and St James's Place adding 7.5%. Housebuilders also rose, with Persimmon, Barratt Developments and Taylor Wimpey rising 6.5%, 5.9% and 6.4% respectively.

ConvaTec was the best performer, adding 9.0%.

The medical products and technologies company said revenue in the 10 months to October 31 rose 2.4% year-on-year, slowing from a 3.6% hike in the first-half due to adverse effects from foreign exchange movements.

Nonetheless, ConvaTec upped its 2022 organic revenue growth guidance to a 5.4% to 5.8% range, from previous a 4.0% to 5.5% forecast.

In the midcaps, IntegraFin added 11%. The London-based investment platform said it expects to report adjusted pretax profit "moderately above" the top end of analyst consensus estimates.

This follows cost reductions resulting from accounting updates, the firm explained.

Grafton jumped 11% as it backed yearly guidance and unveiled a new share buyback of up to GBP100 million.

"The favourable first half revenue trends in the Distribution businesses in Ireland and the Netherlands continued against the backdrop of solid underlying demand and building materials price inflation," the building materials firm and DIY retailer said.

Average daily like-for-like revenue grew 1.8% annually at constant currency during the period from July 1 and October 31. It was up 17% from three years earlier, before the onset of the pandemic.

On AIM, Biome Technologies surged 62%.

The plastic material & resin manufacturing company said revenue in the third quarter of 2022 is in-line with expectations at GBP1.9 million, and 73% higher than the GBP1.1 million achieved the previous year.

It explained that the rise reflected demand across its customer portfolio, as well as some catch-up from the second quarter as raw materials for production finally cleared supply chain hurdles.

Biome confirmed that its outlook for 2023 remains unchanged.

In Friday's UK corporate calendar, there's half year results from insurer Beazley and warehouse investor Urban Logistics REIT. There will also be trading statements from financial services firm Permanent TSB and toys, crafts and stationery retailer TheWorks.co.uk.

The economic calendar for Friday has UK monthly GDP estimates, production index, and trade statistics, as well as German consumer inflation figures at 0700 GMT.

By Elizabeth Winter; elizabethwinter@alliancenews.com

Copyright 2022 Alliance News Limited. All Rights Reserved.

More News
26 Feb 2024 08:25

GSK gonorrhoea treatment achieves efficacy endpoint in latest trial

(Alliance News) - GSK PLC on Monday announced positive results from the latest trial of its oral gonorrhoea treatment, showing it to be on par with intramuscular therapies.

Read more
26 Feb 2024 07:22

GSK reports positive results from gonorrhoea treatment trial

(Sharecast News) - GSK announced encouraging headline outcomes from its trial of gepotidacin, an oral antibiotic aiming to address uncomplicated urogenital gonorrhoea in adolescents and adults, on Monday.

Read more
21 Feb 2024 09:47

GSK reports encouraging results for ViiV's Cabenuva HIV treatment

(Alliance News) - GSK PLC on Wednesday said that its majority-owned company ViiV Healthcare had received positive interim data from ongoing trials of its injectable HIV treatment.

Read more
21 Feb 2024 07:22

GSK's ViiV sees success in latest HIV treatment trial

(Sharecast News) - GSK's specialist HIV unit ViiV Healthcare, which it owns in partnership with Pfizer and Shionogi, unveiled promising findings from the 'LATITUDE' phase three trial of its long-acting injectable HIV treatment Cabenuva on Wednesday.

Read more
20 Feb 2024 15:10

PRESS: AJ Bell founder to join Applied Nutrition ahead of IPO - Sky

(Alliance News) - Supplements maker Applied Nutrition, plotting a London stock market float, is to add AJ Bell PLC founder Andy Bell as its chair, Sky News reported on Tuesday.

Read more
20 Feb 2024 08:55

IN BRIEF: Diageo welcomes GSK's CFO as non-executive director

Diageo PLC - London-based brewer and distiller sells more than 200 drinks brands, including Guinness stout, Captain Morgan rum and Johnnie Walker whisky - Appoints GSK PLC's chief financial officer and executive director, Julie Brown, as a non-executive director. Says she will succeed Alan Stewart as chair of the audit committee after his retirement following the firm's annual general meeting in September. Chair Javier Ferran says: "Julie brings many years of experience in financial, commercial and strategic roles in international companies operating in highly regulated industries. She is strongly committed to enabling diversity in business and to creating sustainable, long-term value for stakeholders. I look forward to her contribution to Board discussions and to working with her in progressing Diageo's ambition to be one of the most trusted and respected consumer products companies in the world."

Read more
15 Feb 2024 14:44

UK dividends calendar - next 7 days

Friday 16 February 
JPMorgan Asia Growth & Income PLCdividend payment date
JPMorgan Japan Small Cap Growth & Income PLCdividend payment date
Murray International Trust PLCdividend payment date
Premier Miton Group PLCdividend payment date
Schroder Oriental Income Funddividend payment date
Solid State PLCdividend payment date
Monday 19 February 
no events scheduled 
Tuesday 20 February 
Invesco Bond Income Plus Ltd 
Wednesday 21 February 
no events scheduled 
Thursday 22 February 
abrdn Asia Focus PLCex-dividend payment date
Alumasc Group PLCex-dividend payment date
AstraZeneca PLCex-dividend payment date
BlackRock Throgmorton Trust PLCex-dividend payment date
Braemar PLCex-dividend payment date
easyJet PLCex-dividend payment date
Ecofin US Renewables Infrastructure Trust PLCex-dividend payment date
Endeavour Mining PLCex-dividend payment date
FRP Advisory Group PLCex-dividend payment date
Gateley Holdings PLCex-dividend payment date
GSK PLCex-dividend payment date
Hercules Site Services PLCex-dividend payment date
Jersey Electricity PLCex-dividend payment date
Land Securities Group PLCex-dividend payment date
Molten Ventures VCT PLCex-dividend payment date
Northern Bear PLCex-dividend payment date
Redrow PLCex-dividend payment date
Samuel Heath & Sons PLCex-dividend payment date
Titon Holdings PLCex-dividend payment date
Unilever PLCex-dividend payment date
Van Elle Holdings PLCex-dividend payment date
Virgin Money UK PLCex-dividend payment date
Witan Investment Trust PLCex-dividend payment date
  
Comments and questions to newsroom@alliancenews.com
  
A full 21-day events calendar is provided each day with a subscription to Alliance News UK Professional.
  
Copyright 2024 Alliance News Ltd. All Rights Reserved.

Read more
15 Feb 2024 11:02

Berenberg hikes target price on GSK

(Sharecast News) - Analysts at Berenberg hiked their target price on drugmaker GSK from £16.50 to £18.20 on Thursday, stating the group was moving closer to offsetting losses associated with the expiry of its patent on HIV drug dolutegravir.

Read more
15 Feb 2024 09:45

LONDON BROKER RATINGS: Jefferies cuts Kingfisher but Citi raises

(Alliance News) - The following London-listed shares received analyst recommendations Thursday morning and Wednesday:

Read more
15 Feb 2024 08:49

GSK completes USD1.4 billion purchase of respiratory firm Aiolos Bio

(Alliance News) - GSK PLC on Thursday said it has completed the acquisition of Aiolos Bio Ltd, expanding its respiratory portfolio with a potential "best-in-class" asthma treatment.

Read more
13 Feb 2024 16:53

LONDON MARKET CLOSE: Stocks in red amid sticky US inflation data

(Alliance News) - Stock prices in London closed in the red on Tuesday, after a key US inflation reading came in hotter-than-expected.

Read more
13 Feb 2024 16:21

London close: Stocks fall as US inflation tops expectations

(Sharecast News) - London markets ended the trading day in negative territory on Tuesday, influenced by concerns over higher inflation figures from the United States and a deceleration in wage growth within the UK.

Read more
13 Feb 2024 16:21

London close: Stocks fall as US inflation tops expectations

(Sharecast News) - London markets ended the trading day in negative territory on Tuesday, influenced by concerns over higher inflation figures from the United States and a deceleration in wage growth within the UK.

Read more
13 Feb 2024 12:06

LONDON MARKET MIDDAY: Stocks fall but pound up before US data

(Alliance News) - Stock prices in London were on the decline on Tuesday afternoon, with sentiment tetchy ahead of a US inflation report later.

Read more
13 Feb 2024 09:45

Citi ups recommendation on GSK to 'buy'

(Sharecast News) - Citi has upgraded its rating on vaccines and drugs blue chip GSK to 'buy' while also boosting its earnings estimates.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.